Core Viewpoint - CAMP4 Therapeutics Corporation has announced the pricing of its underwritten offering of 5,000,000 shares of common stock at $6.00 per share, aiming to raise gross proceeds of $30.0 million to support its product development and general corporate purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about December 19, 2025, pending customary closing conditions [2]. - All securities in the offering are being sold by the Company, with participation from both new and existing investors, including notable firms like Janus Henderson Investors and EcoR1 Capital [3]. - Leerink Partners is acting as the sole underwriter for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash and marketable securities, will primarily be used to support continued development activities for the Company's product candidates and for general corporate purposes [2]. Group 3: Company Overview - CAMP4 Therapeutics is focused on developing regulatory RNA-targeting therapeutics aimed at upregulating gene expression to treat a variety of genetic diseases [6]. - The Company utilizes its proprietary RAP Platform® to map regulatory RNAs and create therapeutic candidates targeting genes associated with over 1,200 disorders, where a modest increase in protein expression could be clinically significant [6].